FDA removing lovo-cel partial hold a positive for Bluebird, says Morgan Stanley

Morgan Stanley analyst Matthew Harrison noted that Bluebird Bio announced that the FDA removed the partial hold for lovo-cel in patients under the age of 18 with sickle cell disease and that management plans to resume enrollment and treatment of patients ages 2-17. While calling the removal of the partial clinical hold "a positive," Harrison awaits further updates on enrollment progress and keeps an Underweight rating and $3 price target on Bluebird shares.